- What are the pitfalls of binding analysis with DSF based on RT-qPCR
- How early-on sample QC and optimization of assay conditions can improve success rate in interaction analysis
- How SUPR-DSF technology can be used as a first pass assay for screening and ranking of binders including auto-fluorescent compounds
SUPR-DSF: a new tool to screen and profile binding interactions
May 31, 2023 | 10:30 - 11:30 ET | Virtual
About The Event
Interaction analysis is in the center of Structural Biology and Drug Discovery projects in academia and industry. There are multiple questions concerning binding interactions and states of the binding partners that are to be addressed: • Is protein stable in buffers with different composition? • What about protein’s tolerance of organic solvents (e.g. DMSO)? • Is there any binding? • What is the binding affinity and kinetics? • What is the binding mechanism? • What is the energetics of the binding? • Is a structural change involved? There are multiple technique and approaches to binding analysis that exist to suit the needs of a particular project and a project stage. One of the recognized challenges is identification of binders for an extended follow up characterization and optimization. A large number of biophysical (NMR, SPR, GCI, DSF, MS) and biochemical approaches are used. Despite the progress with biophysical technologies, many of them may require some method development, dedicated reagents and skilled operators to run and interpret the data. SUPR-DSF provides a first pass technology for screening and ranking of binders. The technology reads intrinsic fluorescence spectra directly from 384-well plates as samples of target protein with and without compounds are subjected to a controlled-up scan of temperature. It requires no or minimal assay development and is run without use of reagents. In this webinar scientists from Biophysical screening and characterization facility at SciLife Laboratory and Biomedical Center at Uppsala University will share their experience from the use of SUPR-DSF in their projects focused on Structural Biology and Fragment-based Drug Discovery.
Who should attend?
Scientists and project leaders in industry and academia working on interaction analysis in the context of Structural Biology and Drug Discovery research.
What will you learn?